Current Hematologic Malignancy Reports

, Volume 1, Issue 3, pp 141–151

Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate

Authors

    • Division of Hematology/Oncology, Karmanos Cancer InstituteWayne State University School of Medicine
  • Charles A. Schiffer
Article

DOI: 10.1007/s11899-996-0002-y

Cite this article as:
Zonder, J.A. & Schiffer, C.A. Curr Hematol Malig Rep (2006) 1: 141. doi:10.1007/s11899-996-0002-y

Abstract

Imatinib (imatinib mesylate, Gleevec® [formerly known as STI571], Novartis Pharmaceuticals, Basel, Switzerland) is a protein tyrosine kinase inhibitor that is approved by the US Food and Drug Administration for patients with all phases of chronic myeloid leukemia (CML). Imatinib is remarkably effective as treatment for CML in the chronic phase (at a dosage of 400 mg/d) and the accelerated phase (at 600 mg/d). At this time, it remains to be seen whether the chronic phase of CML can be extended sufficiently in some patients so that they are functionally "cured," and also whether the increased rate of major molecular response induced by doses of imatinib higher than 400 mg/d will further improve overall survival of patients with CML in the chronic phase. The value of molecular monitoring of response in patients with CML in the chronic phase is examined. Although imatinib 800 mg/d can induce dramatic responses in patients with myeloid blast crisis, lymphoid blast crisis, and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the responses are usually incomplete and of short duration. We discuss the role of imatinib in relation to allogeneic stem cell transplantation (particularly in younger patients), recognizing that the data upon which any decisions can be made are relatively immature. Finally, recent data on new tyrosine kinase inhibitors capable of overcoming primary or acquired resistance to imatinib are reviewed.

Copyright information

© Current Science Inc 2006